HYDI Hydromer Inc.

Hydromer and N8 Medical Partner to Bring Life-Saving Coated ET Tubes for COVID-19 Patients

Hydromer and N8 Medical Partner to Bring Life-Saving Coated ET Tubes for COVID-19 Patients

CONCORD, NC, April 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Hydromer (OTCQB: ) announced today that it will be the exclusive coating supplier and manufacturing partner for N8 Medical’s CeraShield™ Endotracheal Tube. Health Canada has granted emergency use access marketing approval for the CeraShield™ Endotracheal Tube for all Canadian mechanically-ventilated COVID-19 patients.

N8's CeraShield™ tube has a patented anti-fouling coating to prevent deadly bacterial infections that frequently occur in ventilated patients. Conventional endotracheal tubes allow pathogenic bacteria to rapidly grow on the tube surfaces and are a source of infection that may lead to acute kidney injury, sepsis and death.

“N8’s CeraShield™ Endotracheal Tube may reduce secondary bacterial infections, save lives and expand ventilator resource capacity by getting patients off ventilators sooner,” said Ronald Bracken, N8’s President and Chief Operating Officer. “We are pleased that Health Canada is now allowing all hospitals to have access to this potentially life-saving technology.”

CAUTION: In the United States, the CeraShield™ Endotracheal Tube is investigational and has not been granted marketing approval. These statements have not been evaluated by Health Canada or FDA.

About Hydromer®

Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients’ products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients’ needs. Hydromer is also manufacturing their own brand of hand sanitizer under the brand.

About N8 Medical

N8 Medical, LLC (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.

If you have an interest in coating your devices or the CeraShield™ endotracheal tubes, please contact us right away!

Email us at  Or call us at 800-326-5976.

 

EN
24/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hydromer Inc.

 PRESS RELEASE

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Thi...

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 CONCORD, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain preliminary, unaudited management-prepared financial results for the quarter ended September 30, 2024. These results are based on the most current information available to management, are unaudited, and are subject to the completion of the Company’s 2024 year-end ...

 PRESS RELEASE

Hydromer, Inc. Announces the Restructuring and Formation of World-Clas...

Hydromer, Inc. Announces the Restructuring and Formation of World-Class Research and Development Division to Drive Innovation and New Product Development ·       Company introduces a top-tier team of chemists to lead innovation in hydrophilic coatings and develop cutting-edge, environmentally friendly solutions ·       Restructured R&D division, under new leadership, aims to enhance product offerings, improve operational efficiency, and drive future growth CONCORD, N.C. , Oct. 21, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI), a leader in hydrophilic coating technologie...

 PRESS RELEASE

Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Fin...

Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update CONCORD, NC, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain Corporate Highlights and preliminary, unaudited management-prepared financial results for the quarter ended June 30, 2024. These results are based on the most current information available to management, are unaudited and are subject to ch...

 PRESS RELEASE

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Fir...

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 CONCORD, NC, April 29, 2024 (GLOBE NEWSWIRE) -- via -- Hydromer, Inc. (OTC: HYDI) (the “Company”), a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce certain preliminary, unaudited management-prepared financial results for the quarter ended March 31, 2024. These results are based on the most current information available to management, are unaudited, and are subject to the completion of the Company’s 2024 year-en...

 PRESS RELEASE

Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Co...

Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Contract Extensions, and the Launch of New Innovations CONCORD, NC, Jan. 16, 2024 (GLOBE NEWSWIRE) -- via – Hydromer, Inc. (OTC: HYDI) Hydromer, Inc. (the “Company”) is pleased to provide the following update to shareholders regarding the Company’s progress toward stability and profitable growth. Much has been done since the spring of 2023 in reducing the Company’s overhead and operating costs, which management believes will lead to improved profitability in the current fiscal year. Additionally, investment in new prod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch